LY3532226
18835
Phase 1 small_molecule completed
Quick answer
LY3532226 for Obesity is a Phase 1 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Obesity
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed